Two pregnancies in partners of thalidomide users that have occurred in the first year after launch did not violate requirements of System for Thalidomide Education and Prescribing Safety Program, Celgene says. Conception occurred 35 days and 65 days after discontinuation of treatment. Thalomid labeling requires contraception for one month prior to therapy, during therapy and for one month following therapy. Celgene said it immediately reported the cases to FDA. FDA presented Thalomid as an example of managing postmarketing risk of drugs at its Science Forum Feb. 15
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth